GT Biopharma, Inc. Research And Development Expense

• GT Biopharma, Inc. showed a decrease of -40.1% in Research And Development Expense from 2024 to 2025.
• This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), GT Biopharma, Inc.'s Research And Development Expense has grown by 1,839.7%.
• Historical annual values: Fiscal year 2025: $3.47 million | Fiscal year 2024: $5.80 million | Fiscal year 2023: $6.47 million | Fiscal year 2022: $8.81 million | Fiscal year 2021: $9.59 million | Fiscal year 2020: $485.0 thousand | Fiscal year 2019: $1.67 million | Fiscal year 2018: $9.07 million | Fiscal year 2017: $1.07 million | Fiscal year 2016: $975.0 thousand | Fiscal year 2015: $1.00 million | Fiscal year 2014: $0.00 | Fiscal year 2013: $0.00 | Fiscal year 2012: $0.00 | Fiscal year 2011: $17.0 thousand | Fiscal year 2010: $179.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026